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Tau Accumulation Causes Mitochondrial Distribution
Deficits in Neurons in a Mouse Model of Tauopathy
and in Human Alzheimer’s Disease BrainKatherine J. Kopeikina,*† George A. Carlson,‡
Rose Pitstick,‡ Adam E. Ludvigson,† Alan Peters,†
Jennifer I. Luebke,† Robert M. Koffie,*
Matthew P. Frosch,* Bradley T. Hyman,* and
Tara L. Spires-Jones*
From the MassGeneral Institute for Neurodegenerative Disease,*
Massachusetts General Hospital, Harvard Medical School,
Charlestown Massachusetts; the Department of Anatomy and
Neurobiology,† Boston University School of Medicine, Boston,
Massachusetts; and the McLaughlin Research Institute,‡ Great
Falls, Montana
Neurofibrillary tangles (NFT), intracellular inclusions
of abnormal fibrillar forms of microtubule associated
protein tau, accumulate in Alzheimer’s disease (AD)
and other tauopathies and are believed to cause neu-
ronal dysfunction, but the mechanism of tau-medi-
ated toxicity are uncertain. Tau overexpression in cell
culture impairs localization and trafficking of organ-
elles. Here we tested the hypothesis that, in the intact
brain, changes in mitochondrial distribution occur
secondary to pathological changes in tau. Array
tomography, a high-resolution imaging technique,
was used to examine mitochondria in the reversible
transgenic (rTg)4510, a regulatable transgenic, mouse
model and AD brain tissue. Mitochondrial distribu-
tion is progressively disrupted with age in rTg4510
brain, particularly in somata and neurites containing
Alz50-positive tau aggregates. Suppression of soluble
tau expression with doxycycline resulted in complete
recovery of mitochondrial distribution, despite the
continued presence of aggregated tau. The effect on
mitochondrial distribution occurs without concom-
itant alterations in neuropil mitochondrial size, as
assessed by both array tomography and electron
microscopy. Similar mitochondrial localization al-
terations were also observed in human AD tissue in
Alz50 neurons, confirming the relevance of tau to
mitochondrial trafficking observed in this animal
model. Because abnormalities reverted to normal if
soluble tau was suppressed in rTg4510 mice, even inthe continued presence of fibrillar tau inclusions, we
suggest that soluble tau plays an important role in
mitochondrial abnormalities, which likely contribute
to neuronal dysfunction in AD. (Am J Pathol 2011, 179:
2071–2082; DOI: 10.1016/j.ajpath.2011.07.004)
Tau, a microtubule associated protein, is the major con-
stituent of neurofibrillary tangles (NFT). These deposits
are the most common neuronal inclusions in Alzheimer’s
disease (AD).1,2 As a result of their correlation with syn-
apse and neuronal loss and severity and duration of
dementia in AD,3–6 NFT have been thought to indicate
neural dysfunction and impending neuronal death. Re-
cent studies oppose this view and suggest that other
pathological changes in tau, such as mislocalization to
the somatodendritic compartment, hyperphosphoryla-
tion, and conformational changes, may be more detri-
mental to neurons than tangles. Animal models have
demonstrated dissociations between NFT, neuronal dys-
function,7 and neuronal loss.8–12 Meanwhile, tau overex-
pression, which results in abnormally high levels of solu-
ble tau throughout the cell in the absence of aggregates,
alters fast axonal transport, particularly in the antero-
grade or kinesin-dependent direction.13–18 This transport
deficit is thought to lead to depletion of necessary mate-
rials, deterioration of the synapse, and a “dying back” of
the neuron.19–21 We previously found in cultured neurons
that alterations in axonal transport due to soluble tau
over-expression resulted in perinuclear clumping of mi-
tochondria.18 Disruptions in mitochondrial distribution,
morphology and function have been linked to several
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neurodegenerative processes.22–28
Studies of axonal transport and mitochondrial distribu-
tion have largely been limited to cell culture models, in
which the effects of soluble tau species versus NFT have
not been determined. In the current study, we tested the
hypothesis that mitochondrial trafficking defects would
occur in vivo as a consequence of tau over-expression
and/or its mislocalization and aggregation, and also
asked whether defects in mitochondrial trafficking could
be detected in human AD. Evidence of an imbalance of
mitochondrial fission and fusion processes has been ob-
served in Alzheimer’s brain,26–31 which could contribute
to mitochondrial dysfunction and changes in mitochon-
drial distribution. We investigated somatic and neuritic
mitochondrial distribution and mitochondrial volumes in
neurons and neuropil of rTg4510 mice, which over-ex-
press a human mutant form of tau (P301L) known to lead
to dementia. The rTg4510 mice demonstrate age-related
cognitive impairment, accumulation of NFT and neuronal
loss but also harbor a doxycycline-regulatory domain that
can be used as an “off-switch” for this mutant tau over-
expression. Doxycycline treatment results in stabilization
of neuronal number and recovery of cognitive function
even in the face of continued accumulation of NFT.9,10
Since mitochondria are quite small, on the order of the
limits of light microscopy, we used a recently developed
high-resolution microscopy technique, array tomogra-
phy, for precise localization of mitochondria as well as
accompanying mitochondrial volume quantification.32,33
Array tomography overcomes the approximate 1 m z-
resolution limitation of conventional confocal, and mul-
tiphoton microscopy, which is larger than the width of a
single mitochondrion, by ultrathin sectioning of samples
into ribbons of 70 nm sections followed by immunofluo-
rescence imaging and three-dimensional reconstructions
of structures of interest. This allows precise quantification
of the number, volume, and protein labeling of small
structures including mitochondria in a high-throughput
automated fashion with thousands of mitochondria im-
aged per case. Electron micrographs were used to con-
firm mitochondrial volume data derived from the array
tomography method, which validates the use of this au-
tomated technique for volume measurements. We also
applied array tomography to human brain tissue to ob-
serve mitochondrial distribution changes in AD, highlight-
ing the efficacy of this technique for human pathological
analyses.
Our data demonstrate that early in the course of dis-
ease, mitochondrial distribution is altered, particularly in
those cells or neurites bearing aggregates of tau. These
patterns persist and become more severe with age.
Doxycycline treatment of a subset of rTg4510 (regulat-
able transgenic) mice remarkably restored mitochondrial
distribution to near normal, even in the continued pres-
ence of aggregated misfolded tau. Interestingly, these
distribution changes were not accompanied by altera-
tions in mitochondrial volume in the neuropil. Mitochon-
drial distribution in human AD brain demonstrated pat-
terns that mirrored those seen in rTg4510 mice. Taken
together, our findings indicate that mitochondrial distri-bution changes occur in vivo as a consequence of tau
over-expression, and may be predominantly due to sol-
uble tau species.
Materials and Methods
Animals
For this study we used a well-characterized, regulatable
mouse model of tauopathy that over-expresses human
mutant (P301L) tau that can be suppressed with doxycy-
cline (dox) treatment. Mice were generated as previously
described.9,10 The responder transgene contains cDNA
of human four-repeat tau with the P301L mutation down-
stream of a tetracycline-operon-responsive element
(TRE). The activator transgene consists of a tet-off open
reading frame downstream of Ca2 calmodulin kinase II
promoter elements. This bigenic system results in over-
expression of human mutant tau in forebrain structures
when both promoter and activator are present. Littermate
animals with only the activator transgene, which don’t
over-express tau were used as controls. Two age groups,
5.5 and 8.5 month old, of tau over-expressing (rTg4510)
and control animals (nonTg) were used (n  4 per
group). Doxycycline was administered at 200ppm in the
food for 6 weeks between 7 and 8.5 months of age in a
subset of rTg4510 and nonTg animals (n  4 per group),
leading to suppression of tau as previously described.9
Animals were housed and treated in accordance with
institutional guidelines and those of the National Institutes
of Health.
Human Brain Tissue
Tissue from the superior temporal gyrus of subjects with
either an AD diagnosis or no cognitive impairment was
obtained from the Alzheimer Disease Research Center at
Massachusetts General Hospital. All human tissue was
handled in agreement with local and national IRB guide-
lines. Ten AD cases (61–90 years of age) and four cog-
nitively normal controls (62–75 years of age) were in-
cluded in this study (Table 1).
Sample Preparation
Tissue was prepared for array tomography as previously
described.32–34 Brains were removed from mice immedi-
ately after euthanasia by CO2 inhalation. Human tissue
samples were collected within 24 hours of autopsy. Small
blocks (1 mm3) of primary somatosensory cortex from
mice or temporal cortex from human cases were fixed by
immersion in 4% paraformaldehyde and 2.5% sucrose in
phosphate-buffered saline solution (PBS) for 3 hours at
room temperature. Tissue was then dehydrated through a
graded series of ethanols, and into LRWhite resin (Elec-
tron Microscopy Sciences, Hatfield PA), embedded in
gelatin capsules with LRWhite and polymerized at 53C
for 24 hours. Blocks were then removed from gelatin
capsules and cut into ribbons of 7 to 150 ultra-thin 70 nm
sections with a Jumbo Histo Diamond Knife (Diatome,
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(Fisher Scientific, Pittsburgh PA; 12-544-E; No. 1.5; 0.16-
to 0.19-m thick).
Immunohistochemistry and Microscopy
Immunostaining for analysis of mitochondrial localization
was performed as follows for both mouse and human
cases. Ribbons were washed in 50 mmol/L glycine in Tris-
buffered saline (TBS) and blocked in 0.05% Tween and
0.1% BSA in TBS. Primary antibodies mouse IgM Alz50 (a
generous gift of Peter Davies, Albert Einstein College of
Medicine), mouse IgG anti-tubulin (Sigma, St. Louis MO),
and rabbit anti-VDAC/porin (Abcam, Cambridge MA)
were diluted 1:50 in block buffer and applied to ribbons
for 2 hours then rinsed off with TBS. Fluorescent second-
ary antibodies, donkey anti-mouse IgM Cy3, donkey anti-
mouse IgG Alexa-Fluor 488, and donkey anti-rabbit Cy5
(Jackson ImmunoResearch, Westgrove PA) were diluted
1:100 in block buffer and incubated on ribbons for 30
minutes. 1024  1024 pixel images of regions of inter-
est (cell bodies or neurites) within a single 70 nm
section were acquired with a Leica DMRE confocal
microscope (Wetzlar, Germany) and a 63  1.4 numer-
ical aperture Plan Apochromatic oil objective.
For analysis of mitochondrial volume, ribbons of at
least 10 ultrathin sections were stained as described
above with rabbit anti-VDAC/porin (Abcam) at 1:200 fol-
lowed by fluorescent secondary donkey anti-rabbit Cy3
at 1:100. Areas of interest, containing cell bodies (used
as fiduciary markers) were imaged on 10 to 12 serial
sections. Images of 1024  1024 pixels were collected
with a Zeiss Axioplan LSM510 confocal/multiphoton mi-
croscope (Ziess, Thornwood, NY) with a 63  1.2 numer-
ical aperture Plan Apochromatic water objective.
To confirm that astrocytic processes were not included
in analyses, we performed two array immunostains of
rTg4510 mouse tissue as described above but using the
following antibodies. The first included mouse IgM Alz50
Table 1. AD Diagnoses in 10 Patients
Case Age Sex Diagnosis
1 75 M No cognitive impairment (prior
stroke in contralateral
hemisphere)
2 66 M No cognitive impairment
3 69 M No cognitive impairment
4 62 M No cognitive impairment
5 89 M AD; Braak stage VI/VI
6 61 M AD; Braak stage V/VI
7 77 M AD; Braak stage V/VI
8 74 F AD; Braak stage VI/VI
9 90 M AD; Braak stage IV/VI
10 80 F AD; Braak stage VI/VI
11 83 F AD; Braak stage VI/VI
12 84 M AD; Braak stage V/VI
13 81 M AD; Braak stage VI/VI
14 84 F AD; Braak stage VI/VI
Braak staging defines pathological progression of AD in six stages
(I-VI), with VI being the most severe.
AD, Alzheimer’s disease; F, female; M, male.(1:100), mouse IgG anti-tubulin (1:300), rabbit anti-glialfibrillary acidic protein (1:300; Sigma), and secondaries
goat anti-rabbit Cy3, goat anti-mouse IgG Alexa-Fluor
488, goat anti-mouse IgM Cy5 (1:100) and DAPI (Invitro-
gen, Eugene OR). The second included mouse IgM
Alz50 (1:100), rat anti-tubulin (1:100; Abcam), mouse
anti-glutamine synthetase (1:50; Millipore, Billerica MA)
and secondaries goat anti-mouse IgG Alexa-Fluor 488
(1:50), goat anti-rat Cy3 and goat anti-mouse IgM Cy5
(1:100) and DAPI. Single section images of 1024  1024
pixels were collected with a Zeiss Axioplan LSM510 con-
focal/multiphoton microscope with a 63  1.4 numerical
aperture Plan Apochromatic oil DIC objective.
For whole cell reconstruction by array tomography a
ribbon of 150 80 nm sections was stained as described
previously with rabbit anti-VDAC/porin (1:300), mouse
IgG anti-tubulin (1:300), and mouse IgM Alz50 (1:100)
followed by goat anti-rabbit Alexa Fluor 488 (1:100),
chicken anti-mouse IgG Alexa-Fluor 647 (1:300), goat
anti-mouse IgM Cy3 (1:100) and DAPI. A region of inter-
est (1024  1024 pixels, zoom 3) containing the en-
tirety of an Alz50 and neighboring Alz50 cell was
serially collected from each of 109 sections with a
Zeiss Axioplan LSM510 confocal/multiphoton micro-
scope and a 63  1.4 numerical aperture Plan Apo-
chromatic oil DIC objective.
Electron Microscopy
Electron micrographs of two 8.5-month-old rTg4510 and
one age-matched nonTg were acquired as previously
described.35 In short, mice were anesthetized with an
intraperitoneal injection of sodium pentobarbital and tran-
scardially perfused with fixative solution containing 1%
paraformaldehyde and 1.25% glutaraldehyde in 0.1M ca-
codylate buffer (pH 7.2–7.4) at 37°C. Following perfusion,
the heads of the mice, with calvaria removed, were sub-
merged in a solution of 2% paraformaldehyde and 2.5%
glutaraldehyde in 0.1M cacodylate buffer and kept at 4°C
for 12 hours. One-millimeter thick coronal slices of the
dorsal premotor cortex were obtained and divided into
smaller pieces for embedding. Tissue was rinsed in 0.1M
sodium cacodylate buffer, osmicated with 1% osmium
tetroxide in cacodylate buffer, dehydrated through as-
cending ethyl alcohol concentrations, rinsed with propyl-
ene oxide and immersed in 1:1 propylene oxide and
Araldite 502 plastic (Ernest F. Fullam, Inc, Redding CA)
overnight. Cortical pieces were placed in pure Araldite,
rotated for 6 hours, transferred to Beem capsules and
hardened at 60°C. An RMC MT6000-XL ultramicrotome
(Boeckeler, Tuscon AZ) was used to cut thin sections,
which were mounted on copper grids then stained with
uranyl acetate and lead citrate and photographed using
a JEOL 100S electron microscope (JEOL, USA, Peabody
MA). Negatives were scanned at 800 dpi with an Epson
Perfection V700 photo scanner.
Image Analysis
Images were viewed and analyzed with Image J (National
Institutes of Health open software; http://rsbweb.nih.gov/
ij). Analysis of mitochondrial localization was performed
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neurites were imaged for each animal or human case.
The mitochondrial channel of each image was opened
and re-named for blinded thresholding. Once thresholds
were determined, the tubulin channel was used to identify
and circle the somatic or neuritic cytoplasm (excluding
the nucleus). This region of interest (ROI) was then ap-
plied to the thresholded mitochondrial image and the
‘Analyze Particles’ feature of Image J applied to deter-
mine percentage of the ROI occupied by mitochondria.
For each cell or neurite analyzed, presence or absence of
Alz50 staining was also determined. This percent area
occupied by mitochondria in the soma and neurites is
referred to as mitochondrial distribution and is used as a
readout for the ability of mitochondria to be trafficked to
all parts of the cell body and neurites as in our previous
study, which showed changes in mitochondrial distribu-
tion in the soma and axon were associated with reduced
anterograde trafficking of mitochondria and fewer mito-
chondria reaching the periphery of the cell body (result-
ing in perinuclear clumping) and fewer reaching the
axon.18
In the whole cell reconstruction, the tubulin images
were opened sequentially and converted to a stack. An
ROI for an Alz50 and an Alz50 cell was defined in
each image. These ROIs were then applied to the corre-
sponding, individually thresholded mitochondrial channel
image and the ‘Analyze Particles’ feature of Image J
applied to determine percentage of the ROI occupied by
mitochondria. The area of each ROI was also measured.
These outputs were used to calculate a percent volume
fraction occupied by mitochondria in an Alz50 and an
Alz50 cell (sum of total area occupied by mitochondria
in each section multiplied by 0.08 divided by the sum of
total area of the ROIs multiplied by 0.08).
For analysis of mitochondrial volume,32 images from
each ribbon were opened sequentially, converted to a
stack and aligned with the MultiStackReg and StackReg
plugins (courtesy of B. Busse and36). Crop boxes (10.01
m2) of neuropil were selected so as to exclude neuronal
cell bodies or other obscuring features, realigned and
re-cropped to exclude empty space created by realign-
ment. Crops were thresholded and run through an auto-
mated, threshold based detection program that counts
puncta appearing in more than one consecutive section
and reports dimensions of each (WaterShed program
provided by B. Busse, S. Smith, and K. Micheva, Stanford
University). Two cortical blocks from the somatosensory
cortex from each 8.5-month-old rTg4510 and control
mouse (n  4 per group) were imaged, yielding 45 crop
boxes.
To confirm the accuracy of the threshold based detec-
tion program, mitochondrial volumes were confirmed by
electron microscopy. All mitochondria in two images for
each of the three animals, accounting for greater than
600 mitochondria, were measured at their widest and
longest points with the line-measuring tool of Image J
after setting the scale (157.48 pix/m for 5,000x magni-
fication and 125.98 pix/m for 4,000x magnification). Es-
timates of the ellipsoidal volume of the mitochondria were
calculated with the following formula 4/3 x r1  r2  r3,with r1 and r2 each representing ½ the length and width,
respectively, and r3 estimated as ½ the shorter of the two
measurements.
Also in these electron micrographs, the cytoplasm of
each cell was defined as an ROI and its area measured.
The sum of the areas of each of the mitochondria mea-
sured within this ROI was used to calculate an approxi-
mation of the mitochondrial percent area fraction in NFT
and NFT cells in control and rTg4510 mice (n  2
NFT, 4 NFT).
Statistics
For mitochondrial distribution analysis, area fraction of
cytoplasm occupied by mitochondria was recorded for
each soma or neurite and grouped by age, genotype,
treatment and whether or not aggregated tau was pres-
ent (Alz50/). Automated mitochondrial volume output
were recorded and grouped by genotype. Mitochondrial
volume distribution was then compared to the measure-
ments acquired by electron microscopy. Normality of
data was assessed with a Shapiro-Wilks test. Mann-Whit-
ney U-tests were applied to non-normal data (mitochon-
drial distribution) and student’s t-test to normally distrib-
uted data (mitochondrial volumes). Significance was
determined as P  0.05. Non-normally distributed data
are presented as box plots, which display the median
value (line inside the box), upper quartile (top of the box),
lower quartile (bottom of the box), 90th percentile (top
whisker), 10th percentile (bottom whisker), with all values
below the 10th and above the 90th percentile (potential
outliers) shown as dots. Normal data are shown as bar
graphs of the mean with SD.
Results
Age-Dependent Disruption of Mitochondrial
Distribution with Aggregated Tau
We used array tomography32–34 on the rTg4510 mouse
brain9,10 to determine somatic and neuritic mitochondrial
distribution. This can be used as an indirect assessment
of neuronal transport18 in the presence of over-ex-
pressed human mutant tau. Array tomography uses ul-
trathin sections to provide a physical z-axis resolution
that is10 times greater than that obtained with standard
or even confocal light microscopy techniques. Recon-
structions of whole cells (Figure 1; see also Supplemental
Video S1 at http://ajp.amjpathol.org) show mitochondrial
distribution throughout the somatic cytoplasm of neurons
without pathological tau accumulation (Alz50) which
appears reduced in neurons with tau pathology (Alz50).
The 3D reconstructions using array tomography on over
100 serial sections require extensive sectioning and im-
aging time, thus we compared the volume fraction of
mitochondria in whole cell 3D volumes with the area
fraction of mitochondria in single 70 nm array sections
and found them to be almost identical. The percent vol-
ume fraction calculated for both the Alz50 and Alz50
cells were within 2% of those generated by single section
nsional
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tomography as a valuable technique for quickly acquiring
large quantities of precise data on mitochondrial distri-
bution.
Using single sections from array tomograms, neurons
of the somatosensory cortex of 5.5 month-old rTg4510
mice were investigated as a model of early disease, as at
this age, this region has not suffered significant neuronal
loss although some NFT are present.10 Percent area frac-
tion of the cytoplasm of soma and neurites occupied by
mitochondria was compared across neurons with patho-
logical tau accumulation (Alz50 cell bodies and neuro-
pil threads) and those without tau pathology (Alz50)
and cell bodies and neurites in wild type littermate con-
trols. A decrease in the percentage of the cytoplasm
occupied by mitochondria was interpreted as a neuronal
transport deficit resulting in perinuclear clustering of mi-
tochondria and reduction in mitochondrial content in neu-
rites.18 As shown in Figure 2A and C, Alz50 cell bodies
Figure 1. Three-dimensional analysis of mitochondrial content of neurons u
images of an Alz50 cell (A) and a nearby Alz50 cell (B) from rTg4510 brai
which appears reduced in Alz50 cells. Panels C and D show partial 3-dime
by the white lines. Scale bars  5 m.demonstrate significant (*P 0.05) reduction in cytoplas-mic area-fraction occupied by mitochondria in compari-
son to neurons of nonTg animals. A trend, which was
statistically not significant, toward a reduction in Alz50
cells in comparison to Alz50 neurons within rTg4510
cortex was also seen at this age (P  0.09). These data
suggest that pathological accumulation of tau influences
mitochondrial distribution in the cell body. These findings
support the suggestion that mitochondrial distribution al-
terations are an early pathogenic step in neurodegenera-
tive processes.24,28
Analysis of mitochondrial distribution in neurites shows
that regardless of whether or not aggregated tau was
present, neurites in rTg4510 cortex were significantly de-
pleted of mitochondria (Figure 2, B and D). Alz50 neu-
rites exhibited significantly reduced neurite area fraction
occupied by mitochondria when compared to neurites of
nonTg animals (P  0.05). Neuropil thread containing
(Alz50) neurites also displayed a significant decrease
in mitochondrial content (P  0.0001). Within the 5.5
y tomography. Z-stack projections of 99 sequential 80-nm array tomography
ts the perinuclear localization of mitochondria (VDAC/porin) in Alz50 cells
reconstructions through the same cells, the cytoplasm of which are encircledsing arra
n exhibimonth-old rTg4510 neurons, the Alz50 and Alz50
(B). Qu
umulatio
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terms of mitochondrial distribution. Since mitochondrial
mislocalization is evident even in the absence of aggre-
gated tau, these data indicate that though aggregated
tau may influence mitochondrial localization, hyperphos-
phorylated or other pathological forms of tau also con-
tribute to such deficits.
Analysis of mitochondrial distribution within Alz50
and Alz50 cell bodies of rTg4510 mice at 8.5 months of
age (Figure 3A), when pathology is more advanced,
shows that Alz50 neurons have a worsened phenotype
of mitochondrial distribution deficits than present at 5.5
months (P  0.05), with a greatly reduced cytoplasmic
area fraction occupied by mitochondria when compared
to nonTg neurons (P  0.0001). Meanwhile, Alz50 cell
bodies continued to maintain mitochondrial distribution
similar to that of control animals.
In accord with the data from the 5.5 month-old age
group, mitochondria were significantly reduced in neu-
rites, with or without the concomitant presence of ag-
gregated tau (Figure 3B). Alz50 neurites were the
Figure 2. Mitochondrial distribution is disrupted in 5.5-month-old rTg4510 ne
sensory cortex in rTg4510 were used to analyze percent area occupied by
(B) (identifiedwith tubulin staining –white outlines). Scale bars: 10m (A); 5m
mitochondrial fraction (C) and neurites both with and without pathological tau accmost severely affected, demonstrating significantly de-pleted mitochondrial content in comparison to both
nonTg neurites (P  0.0001), and Alz50 neurites (P 
0.05). Alz50, tubulin-stained neurites of rTg4510 also
exhibited aberrant mitochondrial localization with de-
creased area fraction occupied by mitochondria when
compared to neurites of nonTg animals (P  0.05); this
result must be interpreted in the context that it is not
known if some of these Alz50 neurites in rTg4510
mice would be contiguous with a section of neurite that
would be Alz50 outside of the block examined. None-
theless, the more severe effect evident in Alz50 neu-
rites and soma indicates that either tau aggregates are
present in cells with very high levels of soluble tau,
which impairs mitochondrial distribution, or that aggre-
gates themselves block transport. To distinguish be-
tween these possibilities, we treated animals with
doxycycline to reduce soluble tau levels by suppress-
ing its production. Aggregated tau persists with sev-
eral weeks of transgene suppression, allowing the ex-
amination of mitochondrial distribution in structures
with aggregated tau in the context of greatly reduced
rray tomography images of single 70-nm sections from layer II/III of somato-
ndria (stained with VDAC/porin – green) within the soma (A) and neurites
antification reveals that somawith Alz50 tau accumulations (red) have depleted
ns have altered mitochondrial distribution (D). *P  0.0001, **P  0.05.urons. A
mitochosoluble tau levels.
arrow
***P 
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processes, we performed two additional array analyses
for astrocytes (see Supplemental Figure S1 at http://
ajp.amjpathol.org). The pattern of staining with tubulin,
which was used to outline neurites and neuronal cell
bodies for mitochondrial analysis, was completely differ-
ent from glial fibrillary acidic protein or glutamine synthe-
tase, both of which are astrocyte markers. Since the glial
stains and tubulin never overlap, we are confident that
the somata and neurites analyzed are neuronal.
Suppression of Soluble Mutant Tau
Overexpression Ameliorates Aberrant
Mitochondrial Distribution Patterns
The bigenic ‘tet-off’ rTg4510 mouse model allows for sup-
pression of soluble tau over-expression by treatment with
doxycycline (dox). Previous studies have shown that dox
treatment for six weeks can ameliorate cognitive deficits
and halt neuronal loss and reduce tau expression by
Figure 3. rTg4510 neurons at 8.5 months of age have disrupted mitochon
whisker plots demonstrate percent cytoplasm occupied by mitochondria in
rTg4510 and nonTg mice. As with the younger age group, neurites in the
mitochondrial content whereas somatic mitochondrial distribution is only i
treatment allows for recovery of mitochondrial distribution to near that of no
of mitochondrial distribution in single 70-nm sections of untreated 8.5-m
depletion of somatic mitochondrial content in Alz50 cells, indicated by the
following 6 weeks of doxycycline treatment. *P  0.0001, **P  0.005, andapproximately 80% without removing existing aggre-gates.9 We treated a subset of rTg4510 (n  4) and
nonTg (n  4) animals with dox between 7 and 8.5
months of age, then analyzed somatic and neuritic mito-
chondrial distribution as previously described. As shown
in Figure 3, dox treatment resulted in redistribution of
mitochondrial content throughout somatic and neuritic
cytoplasm, even with the continued presence of Alz50
aggregates and neuropil threads. Percent cytoplasmic
area fraction occupied by mitochondria within the soma
of Alz50 cells increased by 139% (P  0.0001), to a
level not significantly different from cells of nonTg. Non-
tangle bearing neurons of the rTg4510 also exhibited a
dramatic increase of 40% in cytoplasmic mitochondrial
content following dox treatment, thereby significantly sur-
passing mitochondrial distribution levels seen even in
nonTg cells (P  0.0001). Dox treatment also increased
area fraction of cytoplasm occupied by mitochondria
within nonTg cells by 24% (P  0.0001), suggesting that
doxycycline may have additional effects on mitochondrial
distribution independent of tau suppression. Since the
tribution, which can be ameliorated with transgene suppression. Box and
) and neurites (B) of both untreated and doxycycline-treated 8.5-month-old
, regardless of whether or not tau aggregates are present, are depleted of
with the presence of aggregated tau. In addition, 6 weeks of doxycycline
ls in both the somata and neurites. Representative array tomography images
rTg4510 (C) and doxycycline-treated 8.5-month-old rTg4510 (D) exhibit
in C, whereas the arrowhead in D indicates recovery to near control levels
0.0001. Scale bars  10 m.drial dis
soma (A
rTg4510
mpacted
nTg leve
onth-olddox-related increase evident in nonTg cells was substan-
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similar dox effects were not seen in other experiments to
be discussed below, we interpret our results as demon-
strating significant redistribution of mitochondrial content
within the cell body due to tau suppression rather than as
non-specific effects of dox treatment. These data sug-
gest that, although presence of Alz50 aggregates may
coincide with mitochondrial distribution deficits, reduc-
tion of the soluble tau species improves this condition,
indicating soluble tau as more influential than aggregated
tau on patterns of mitochondrial localization.
Mitochondrial distribution within neurites of the
rTg4510 was similarly affected by dox treatment. Even
with continued presence of neuropil threads, the cyto-
plasmic area occupied by mitochondria increased from
8.4% to 25.45%, in Alz50 neurites, representing a dra-
matic increase of 303% (P  0.0001). This striking in-
crease in mitochondrial content results in Alz50 neu-
rites no longer being significantly different from neurites
of nonTg wild type mice. In contrast, both non-neuropil
thread containing neurites (Alz50) in the rTg4510 and
neurites in the wild type mice demonstrated a nonsig-
nificant change in mitochondrial content following
doxycycline, suggesting that non-specific dox effects
do not play a critical role in the dramatic mitochondrial
localization changes evident in soma and neurites of
Alz50 cells. These data implicate both soluble tau
over-expression and aggregated tau as influential in
mitochondrial localization. Furthermore, these data
suggest that the presence of aggregated tau may not
exert its effects on mitochondrial distribution by exist-
ing as a space occupying lesion, since mitochondria
are able to redistribute subsequent to suppression of
soluble tau, even in the continued presence of aggre-
gated tau deposits.
Mitochondrial Volume Is Maintained Although
Distribution Alterations Occur
In addition to being indicative of neuronal transport deficits,
changes in mitochondrial distribution have been linked to
disruptions in fission and fusion dynamics thereby influenc-
ing mitochondrial size and number.26–29,37 To assess
whether global changes in fission/fusion dynamics ac-
company the evident transport deficits, we measured
mitochondrial volumes in the neuropil in the 8.5 month-
old rTg4510 and nonTg mice by array tomography.
Nearly 4000 mitochondria were measured and demon-
strated no significant difference in volume between
rTg4510 and nonTg mice (Figure 4). To further evaluate
this observation, obtained using array tomography-de-
rived reconstructions of mitochondria, we compared the
output from array tomography to estimations of volumes
from measurements of mitochondrial profiles in electron
microscopy. The volumes reported from the array tomog-
raphy method were consistent with those measured in
electron microscopy (Figure 4). In addition, mitochondria
measured within the cytoplasm of the cells present in the
electron micrographs (total of 6 cells) were summed to
generate an approximation of a percent area fraction forAlz50 and Alz50 cells of rTg4510 and nonTg mice.
Though absolute values of these measurements were
lower than those obtained by array tomography (presum-
ably due to overlapping fluorescence of adjacent, clump-
ing mitochondria in the cell body), the patterns still
persisted, with cells of nonTg having the highest mito-
chondrial percent area fraction, and Alz50 cells of
rTg4510 having the lowest.
Alterations in Mitochondrial Distribution Are
Evident in Human AD Brain
The rTg4510 mouse model exhibits a 13-fold over-ex-
pression of a human Frontotemporal dementia associ-
ated mutant tau9 and does not present with any amyloid
plaque pathology. To determine whether our findings of
mitochondrial localization in rTg4510 mice could be ex-
trapolated to human AD, we performed array tomo-
Figure 4. Mitochondrial volume is maintained even in the presence of
distribution deficits. Three-dimensional volume reconstructions (A) of 8 70
nm sections immunofluorescently stained for VDAC in 8.5-month-old nonTg
(left) and Tg4510 (right) mice were used to measure volumes of individual
mitochondria in the neuropil. These volume measurements were verified by
comparison with volumes estimated from cross-sectional measurements of
mitochondria on electron microscopy images (B). Each mitochondrion was
measured at its widest and longest points as demonstrated with lines within
the mitochondria beside the arrows. An ellipsoidal volume approximation
was calculated from these diameters. Mitochondrial volumes approximated
from electron micrographs confirmed the mitochondrial volumes obtained
with the automated output of the array tomography method. Quantification
of array volumes of n  3922 mitochondria demonstrated no significant
differences in volumes of individual mitochondria of the neuropil (C) be-
tween 8.5-month-old Tg4510 and nonTg mice (depicted as medians with
SD). Scale bar  2 m.graphic studies in human AD tissue. As shown in Figure 5,
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the soma of Alz50 and Alz50 cells were significantly
decreased from that of healthy control neurons (P 
0.0001). Tangle bearing neurons of human AD brain were
more severely affected than Alz50 neurons (P 
0.0001), in accord with data obtained from the mouse
model. In contrast to the mouse data, is the finding that
Alz50 neurons are also significantly depleted of their
mitochondria in AD brain, a result not seen in either 5.5-
or 8.5-month-old mice. This may be consequent to hu-
man AD cases representing a more severe stage of
disease progression than the 8.5-month-old mice or a
consequence of the additional pathological changes
seen in AD brain, including A plaque accumulation,
soluble oligomeric A burden or progressive synaptic
degeneration and glial activation.
Discussion
Cell culture data in both neurons and non-neuronal cells
link tau over-expression to mitochondrial trafficking defi-
cits,18,38,39 which have been associated with negative
consequences to mitochondrial distribution and function.
Regulation of mitochondrial distribution and function is
essential in neurons, which have higher energy demandsand extended processes, requiring regulated trans-
port.29,40 Dysregulation of these processes has been
shown to result in impaired synaptic function and syn-
apse loss30 and is thus proposed as an early pathogenic
step in AD.22,24,28,41 Here, we tested the hypothesis that
tau mislocalization to the somatodendritic compartment,
and subsequent aggregation, in the intact brain of both a
mouse model of tauopathy and human AD would affect
mitochondrial distribution. Further, we tested the hypoth-
esis that soluble, perhaps in addition to, fibrillar tau would
be important for these changes. As a model of tauopathy,
we used rTg4510 animals, which over-express a human
mutant form of tau leading to neurofibrillary pathology
and neuronal loss.9,10 Our results indicate that aberrant
mitochondrial distribution is evident in neurites of
rTg4510 mice, even at an early stage, regardless of
whether or not aggregated tau is present in the form
of neuropil threads. Meanwhile, the somatic distribution is
less affected with only cells with coincident somatic ac-
cumulation of misfolded tau showing an indication of
perinuclear mitochondrial clumping at 5.5 months. In the
aged rTg4510 mice (8.5 months), a worsening of this
mitochondrial distribution phenotype is observed with fur-
ther decreased mitochondrial area fractions in both neu-
. Somatic mitochondrial distribution is disrupted in neurons in
AD brain. Array tomography images of single 70-nm sections
man control (CTL) (A) and human AD brain (B) reveal mito-
l distribution is altered in both Alz50 and Alz50 neurons
d with control brain (quantified in C). *P  0.0001. Scale bars Figure 5
human
from hu
chondria
compare
10 m.rites and in cell bodies with Alz50 tau accumulations.
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AD brain closely reflects the findings in the mouse model,
with dramatic depletion in mitochondrial cytoplasmic
area fraction in Alz50 cells.
Interestingly, in the regulated mouse line the suppres-
sion of soluble tau expression, which does not remove
the Alz50 aggregates, allows full recovery of mitochon-
drial distribution, thereby supporting an important role for
soluble tau in this process. These data also indicate that
mitochondrial distribution deficits are not the result of
exclusion by space occupying aggregates of tau, but
that some other mechanism is involved. The presence of
NFT within the neuronal cell body may represent the
result of reaching a cellular threshold for soluble, mislo-
calized tau accumulation, which our data suggest more
directly interferes with mitochondrial trafficking. Our data
demonstrate an early-onset and pervasive mislocaliza-
tion of mitochondria, which can be alleviated by removing
soluble tau species. In addition, our findings in the
rTg4510 mouse model are mirrored in human AD brain,
and thereby implicate soluble tau, alongside aggregated
forms, as detrimental to normal neuronal function in hu-
man tauopathies such as AD.
The mechanism by which tau over-expression influ-
ences mitochondrial distribution is yet to be precisely
determined. However, our results from the intact rTg4510
mouse brain are consistent with findings from previous in
vitro studies implicating soluble tau over-expression as
detrimental to axonal transport and mitochondrial dis-
tribution and function. The fact that alterations in mito-
chondrial distribution are evident at early stages, in the
5.5 month rTg4510, supports the notion that transport
deficits and accompanying mitochondrial changes in dis-
tribution are early events in neurodegenerative cas-
cades.19,23,24,42,43 Several potential mechanisms for tau
overexpression contributing to transport deficits have
previously been explored. (1) Studies of tau over-expres-
sion in cells and in vitro assays have demonstrated neg-
ative consequences to anterograde cellular transport, by
directly inhibiting progress of kinesin-1, by forming a
“road block” on the microtubule where excessive tau is
bound.14,15,44 (2) Tau-induced trafficking impairments
could also result from destabilization of microtubules due
to hyperphosphorylated tau losing its affinity for the mi-
crotubule.45,46 Microtubule stabilizing compounds such
as taxol have been shown to alleviate tau-induced mito-
chondrial depletion in vitro.47 However, it should be noted
that several studies have demonstrated that microtubule
networks remain intact and stable even with a loss or
complete knock-out of tau,48 suggesting that other mech-
anisms may be involved. (3) Other studies indicate that
tau may interfere with signaling pathways, or molecules
such as GSK3, thereby exerting more indirect control
over transport processes.20,49 Our data support tau-in-
duced anterograde transport deficits as the general
mechanism by which mitochondria become improperly
distributed. The re-distribution of mitochondria following
doxycycline treatment in the rTg4510, even in the contin-
ued presence of neuropil threads or NFT, suggests that
the presence of aggregates of tau may not, in fact, serve
as roadblocks, but rather that soluble tau species inter-fere with mitochondrial trafficking by some other means.
Another mechanism by which tau over-expression may
influence mitochondrial distribution is by interfering with
fission and fusion dynamics. Changes to this equilibrium
can result in mitochondrial and neuronal dysfunction and
synaptic loss or neuronal cell death.26–29 Manipulation of
the primary mammalian fission (fragmentation) GTPase,
dynamin-related protein-1 (Drp-1) has been shown to
result in mitochondrial distribution deficits with perinu-
clear clumping.26,28,30,31,37 It has been posited that ab-
normal proteins present in neurodegenerative diseases,
such as tau, may interact directly with mitochondria
and/or Drp-1 and initiate the cascade of mitochondrial
morphological and functional changes and eventual cel-
lular dysfunction and death.28,37 Interestingly, it has been
demonstrated recently that tau does directly interact with
mitochondria and in this way may influence their distribu-
tion and function.50,51 Furthermore, tau over-expression
in vitro has been shown to result in increased mitochon-
drial fragmentation, alterations in mitochondrial mem-
brane potential, impaired calcium buffering and oxidative
stress responses, and diminished respiratory chain func-
tion.19,43,52 For these reasons, we assessed mitochon-
drial volumes in the 8.5 month-old rTg4510 and nonTg
mice to determine whether concomitant disequilibrium in
fission and fusion dynamics is evident alongside mito-
chondrial distribution deficits. We did not find significant
differences in mitochondrial size in the neuropil, which is
consistent with a proteomic study of P301L mutant tau
over-expressing mice.52 In addition, we confirmed that
the mitochondrial volumes generated by the array tomog-
raphy automated analysis program were similar to those
estimated from electron microscopy measurements, for
both rTg4510 and nonTg mice. These findings suggest
that mitochondrial mislocalization is indicative of tau-in-
duced anterograde transport deficits rather than interfer-
ence with mitochondrial fission and fusion dynamics.
Though our data suggest little change, if any, in mito-
chondrial fission and fusion machinery, the mitochondrial
mislocalization that is evident likely has significant and
deleterious effects on mitochondrial and neuronal func-
tion and survival. Failure to properly distribute mitochon-
dria throughout the cell leaves synapses deprived of their
energy requirements, susceptible to reactive oxygen
species, and with inefficient calcium handling and can
result in synaptic dysfunction and subsequent dying
back of the neuron.15,19,20,53 When improperly distrib-
uted, mitochondria are thought to have impaired func-
tion25,54 and this can lead to increased neuronal suscep-
tibility to excitotoxicity or neurodegenerative stressors
such as amyloid-.2 Changes to mitochondrial distribu-
tion have been linked to failure to maintain mitochondrial
membrane potential, resulting in release and activation of
pro-apoptotic molecules such as caspase. Tau is a
caspase-3 substrate and its cleavage is thought to po-
tentiate oligomerization and enhance tau-induced mito-
chondrial alterations and other negative consequences
to the neuron.1,43,52
Our data also demonstrate several methodological ad-
vances for the field of pathological analyses of mitochon-
dria. First, we confirmed that single section analysis of
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volume fractions from whole cell reconstructions. This
allows for much faster, yet still accurate data collection
with single slice array tomography. We also confirmed
that the automated volume calculations from the immu-
nofluorescent labeled mitochondria in array tomograms
are valid by comparing them to volumes estimated from
measuring mitochondrial profiles on electron micro-
graphs. This is important since array tomography gener-
ates data from thousands of mitochondria per case, al-
lowing analysis of a large sample size, which is
prohibitively time consuming by serial reconstructions in
electron microscopy. Lastly, we applied array tomogra-
phy to human brain tissue collected at autopsy and fixed
according to the array tomography protocols. This tech-
nique was developed for synapse analysis in mice32–34
and has subsequently been adapted for use in ze-
brafish,55 songbirds,56 and on one case of collagen im-
aging in a human optic nerve.57 We demonstrate that in
human brain, array tomography can be used for analysis
of mitochondria and other structures at or near the limit of
z-resolution of conventional microscopy, adding an im-
portant tool in the arsenal of neuropathological analyses.
Taken together, our data support the hypothesis that
tau mislocalization to the somatodendritic compartment
and subsequent aggregation is associated with mito-
chondrial distribution deficits. Furthermore, by suppress-
ing soluble tau species recovery of mitochondrial distri-
bution to near control levels occurs, suggesting that
soluble tau species play a more significant role in mito-
chondrial distribution than aggregated forms. These find-
ings are in agreement with several studies that propose
that oligomeric species are more toxic than aggre-
gates.1,2,8,13,58–60 Meanwhile, tau-induced deficiencies
in mitochondrial distribution are likely a consequence of
axonal transport deficits, and may result in disrupted
mitochondrial and neuronal function and subsequent
synaptic failure and/or cell death. The resemblance of
mitochondrial distribution patterns in neurons in human
AD brain to those in rTg4510 suggests that soluble tau
species play a role in mitochondrial localization in human
neurodegenerative disease and may serve as a useful
therapeutic target.
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